PT  - JOURNAL ARTICLE
AU  - Chao, Chieh-Ju
AU  - Agasthi, Pradyumma
AU  - Seri, Amith R
AU  - Barry, Timothy
AU  - Shanbhag, Anusha
AU  - Wang, Yuxiang
AU  - Eleid, Mackram
AU  - Fortuin, David
AU  - Sweeney, John P.
AU  - Pollak, Peter
AU  - Sabbagh, Abdallah El
AU  - Lester, Steven J.
AU  - Freeman, William K
AU  - Naqvi, Tasneem Z.
AU  - Holmes, David R
AU  - Appleton, Christopher P.
AU  - Arsanjani, Reza
TI  - A novel echo-parameter supersedes the Society of Thoracic Surgeons risk score in predicting 1-year mortality in patients undergoing transcatheter aortic valve replacement
AID  - 10.1101/2021.09.24.21264084
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.24.21264084
4099  - http://medrxiv.org/content/early/2021/09/27/2021.09.24.21264084.short
4100  - http://medrxiv.org/content/early/2021/09/27/2021.09.24.21264084.full
AB  - Objectives We proposed several new echo-parameters (augmented blood pressure) derived from blood pressure and aortic valve gradient measurements and hypothesized that they can accurately predict 1-year mortality post-TAVR.Background In the era of transcatheter aortic valve replacement (TAVR), predicting post-procedural outcome of patients is one of the most important goals in structural heart research.Methods Patients in the Mayo Clinic National Cardiovascular Diseases Registry (NCDR)-TAVR database who underwent TAVR between January 1, 2012 and June 30, 2017 were identified to retrieve baseline demographics, STS risk score, ECG, cardiac computed tomography, echocardiographic and mortality data. Augmented blood pressure parameters and valvulo-arterial impedance were evaluated by Cox regression. After logistic model generation, receiver operating curve analysis was used to assess the model performance against STS risk score.Results The final cohort contained 883 patients with the mean age of 81.3±8.5 years old and 58.2% were male. The mean STS risk score was 8.1±5.1. The median follow-up duration was 353 days and one-year all-cause mortality rates was 13.3%. Multivariate Cox regression showed that augmented SBP and augmented MAP parameters were independent predictors of 1-year mortality (all p<0.0001). A single-parameter model based on augmented MAP1 supersedes STS risk score in predicting 1-year mortality (AUC 0.697 vs. 0.591, p=0.0055).Conclusion Augmented mean arterial pressure provides a simple but effective approach for clinicians to quickly estimate the clinical outcome of TAVR patients and should be incorporated in the assessment of TAVR candidacy.Condensed Abstract We proposed and validated a new echo-parameter, augmented mean arterial pressure, in a cohort contains 883 patients who underwent TAVR between January 1, 2012 and June 30, 2017. Multivariate Cox regression showed that augmented MAP parameters was independent predictors of 1-year mortality (all p<0.0001). A single-parameter model based on augmented MAP supersedes STS risk score in predicting 1-year mortality (AUC 0.697 vs. 0.591, p=0.0055). Augmented MAP provides a simple but effective approach for clinicians to quickly estimate the clinical outcome of TAVR patients and should be incorporated in the assessment of TAVR candidacy.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementNAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board at Mayo Clinic approved the study protocol and research authorization was provided by all the patients to utilize their medical information.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNAAVGaortic valve gradientAugSBPaugmented systolic blood pressureAugMAPaugmented mean arterial pressureCOcardiac outputDBPdiastolic blood pressureMAPmean arterial pressureSBPsystolic blood pressureSVIstroke volume indexSAVRsurgical aortic valve replacementTAVRtranscatheter aortic valve replacementZvavalvulo-arterial impedance